A systematic review of 14 randomized trials involving 3,304 cardiac surgery patients found no meaningful evidence that albumin-based fluids reduce acute kidney injury compared to other fluid regimens, with a posterior probability of benefit at only 18.3%.
Cardiac surgery involving cardiopulmonary bypass (the heart-lung machine) carries significant risk of acute kidney injury (AKI), a complication that increases hospital stay, mortality, and costs. Albumin, a protein-based fluid, has been a standard perioperative choice in cardiac surgery, partly because it theoretically preserves kidney perfusion and function better than crystalloid fluids. This meta-analysis sought to answer whether that theory holds up in practice.
Researchers searched four major medical databases and multiple clinical trial registries through systematic protocol, identifying 14 randomized controlled trials comparing albumin solutions with alternative fluid regimens in adult cardiac surgery patients. Seven of these trials provided data on the primary outcome of perioperative AKI. The pooled analysis yielded a risk ratio of 1.09 (95% credible interval 0.86 to 1.34), meaning albumin showed a numerical 9% increased risk compared to other fluids, though this crossed zero and was not statistically significant. More tellingly, the posterior probability that albumin actually reduced AKI was only 18.3%, well below conventional thresholds for clinical meaningfulness.
The certainty of evidence matters here: four trials had low risk of bias across all domains, suggesting the findings are reasonably robust. The researchers applied Bayesian statistical analysis as the primary approach, which incorporates prior probability and explicitly quantifies uncertainty, alongside conventional frequentist methods. Secondary outcomes including all-cause mortality, intensive care unit stay, hospital length of stay, need for renal replacement therapy, mechanical ventilation duration, and vasopressor support duration showed no significant differences between albumin and other fluids. There were also no meaningful subgroup effects based on trial characteristics, patient populations, or dosing regimens.
This represents a significant null finding because albumin remains expensive compared to crystalloid alternatives and carries risks including volume overload and potential infection transmission (though modern preparations have low pathogen risk). The lack of benefit suggests that simpler, less costly fluid management strategies may be equally effective for preventing kidney injury in this high-risk population. The authors explicitly conclude that other interventions warrant investigation for AKI prevention in cardiac surgery.
If you're facing elective cardiac surgery, this evidence suggests that your surgical team's choice between albumin and crystalloid fluids for perioperative management is unlikely to meaningfully affect your risk of developing acute kidney injury. This is reassuring in one sense: fluid choice appears less critical than other modifiable factors during cardiac surgery.
However, AKI remains a real complication of cardiac surgery, and this meta-analysis essentially tells us that albumin is not the solution. Research attention should instead focus on other potentially modifiable factors: optimizing blood pressure and perfusion pressure during bypass, minimizing contrast dye exposure if coronary angiography is performed, avoiding nephrotoxic medications perioperatively, and maintaining adequate hydration patterns post-operatively. Some evidence supports careful temperature management during bypass as well.
Ask your surgical team about their specific fluid management protocol and whether they've considered other evidence-based AKI prevention strategies. The cost savings from using crystalloids instead of albumin could theoretically be redirected toward other protective measures.
| Detail | Information |
|---|---|
| Study Type | Systematic review and Bayesian meta-analysis |
| Total Participants | 3,304 adults across 14 randomized trials |
| Primary Outcome | Perioperative acute kidney injury (surgery to hospital discharge) |
| Key Finding | Risk ratio 1.09 (95% CrI 0.86-1.34); 18.3% posterior probability of AKI reduction |
| Statistical Approach | Bayesian (primary) and frequentist (secondary) |
| Risk of Bias | 4 of 14 trials rated low risk across all domains |
| Secondary Outcomes | Mortality, ICU stay, hospital stay, renal replacement therapy need, ventilation duration, vasopressor support duration (no significant differences) |
| Journal | Critical Care Science |
| PubMed ID | 42524943 |
Anstey, M. H., Walsham, J., Paton, M., Bellomo, R., & International Best Practice in Perioperative Fluid Management Research Group (2024). Perioperative albumin versus other fluids to prevent cardiac surgery-associated kidney injury: a systematic review and meta-analysis of randomized trials. *Critical Care Science*, 36(1). PubMed: 42524943
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.